AAVarta® AAV capsid in silico evolution discovery platform
Receptor-targeting AAV (RtAAV®) capsids platform
Constellation® AI aided DNA expression cassette design platform
Progress® Data-driven protein engineering platform
BUSINESS INQUIRIES
Exegenesis Bio has developed proprietary discovery and manufacturing platforms to support our research and development programs.
AAVarta® is an in-silico evolution discovery platform.
Utilizing cutting-edge AI technologies to design novel ocular and muscle-tropic AAV capsids by developing larger library space and highly efficient sampling strategy.
RtAAV® is Receptor-targeting AAV (RtAAV) capsids platform for developing Blood-brain-barrier (BBB) penetration with high precision.
Instead of using random short-peptide insertion library-based screening, we have developed a structure-guided human BBB Receptor-targeting AAV capsid screening platform for improving translatability to humans. For example, a clinically validated human transferrin receptor 1(TfR1) has been used a target in our RtAAV platform. And we have successfully generated RtAAV capsids capable of transducing neurons in multiple species (rodents, non-human primates etc.) with high efficiency after intravenous delivery.
Constellation® is an AI aided gene expression cassette design platform.
Achieving tissue-specific regulation through the development of de-targeting microRNAs and synthetic promoters.
Progress® is a data-driven protein engineering platform.
Integrating protein structure modeling and protein stability/activity prediction to engineer novel protein variants with improved activity, stability and immunogenicity.